Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dalton Forms Pact With Ramsey Lake Pharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Dalton Forms Pact With Ramsey Lake Pharma

Will support toxicology studies for VR23 cancer treatment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dalton Pharma Services has signed a drug development and manufacturing contract with Ramsey Lake Pharmaceutical Corp. (RLPC) to support toxicology studies for VR23, their novel β2-targeting proteasome inhibitor in development to treat cancer. The agreement includes the synthesis of VR23 by Dalton as well as the development of analytical testing methods and execution of a stability study.

“We are excited to be moving our lead candidate VR23 into these critical toxicology studies with the help of an experienced, cGMP qualified pharmaceutical development partner,” said Sean Thompson, Ramsey Lake Pharma president and chief executive officer. “Dalton brings nearly 30 years of novel drug development and manufacturing experience to our program.”

Ramsey Lake Pharma is a privately held company committed to the development of novel therapies currently focused on proteasome inhibitors that improve cancer care and result in improved patient outcomes. Its lead candidate, VR23, a small molecule cancer therapeutic, shows strong potential as a next generation proteasome inhibitor, inhibiting tumor growth as a single agent. When used in combination with gold-standard anticancer drugs, VR23 can increase efficacy while reducing toxicity. VR23 also shows potential in overcoming drug resistance. The product was developed in the laboratory of Dr. Hoyun Lee of RLPC.

“Dalton is very pleased to be supporting the advancement of this potentially ground-breaking cancer therapeutic,” said Peter Pekos, chief executive officer and president, Dalton Pharma Services. “This is a great opportunity for two Canadian companies to collaborate on developing innovative products that have the potential to dramatically improve the lives of so many cancer patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics